financetom
Business
financetom
/
Business
/
Scholar Rock Holding Q3 Net Loss Widens
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Scholar Rock Holding Q3 Net Loss Widens
Nov 12, 2024 5:27 AM

08:02 AM EST, 11/12/2024 (MT Newswires) -- Scholar Rock Holding ( SRRK ) reported Q3 net loss Tuesday of $0.66 per diluted share, wider than the $0.53 loss a year earlier.

Analysts polled by Capital IQ expected a loss of $0.60.

The company didn't report any revenue for the quarter ended Sept. 30.

Scholar Rock ( SRRK ) said it had cash, cash equivalents, and marketable securities of about $139.1 million as of Sept. 30, expected to fund operations into Q4 2026.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Asensus Surgical Shares Soar After KARL STORZ Acquisition Offer Announcement
Asensus Surgical Shares Soar After KARL STORZ Acquisition Offer Announcement
Apr 3, 2024
11:15 AM EDT, 04/03/2024 (MT Newswires) -- Asensus Surgical ( ASXC ) shares jumped more than 28% in recent trading after the company said Wednesday that it has entered into a non-binding letter of intent with medical technology company KARL STORZ for a potential acquisition of Asensus. Asensus said that the letter of intent includes the proposal to acquire all...
Merck, Daiichi Sankyo Dose First Person in Phase 2/3 Trial of Raludotatug Deruxtecan to Treat Ovarian Cancer
Merck, Daiichi Sankyo Dose First Person in Phase 2/3 Trial of Raludotatug Deruxtecan to Treat Ovarian Cancer
Apr 3, 2024
11:15 AM EDT, 04/03/2024 (MT Newswires) -- Merck ( MRK ) and Daiichi Sankyo said Wednesday they have dosed the first patient in a phase 2/3 trial assessing the efficacy and safety of investigational drug raludotatug deruxtecan to potentially treat ovarian cancer resistant to platinum-based chemotherapy. The second phase of the study is being done to establish the dose of...
Alto Neuroscience Starts Phase 2 Trial of ALTO-203 in Major Depressive Disorder Patients
Alto Neuroscience Starts Phase 2 Trial of ALTO-203 in Major Depressive Disorder Patients
Apr 3, 2024
11:15 AM EDT, 04/03/2024 (MT Newswires) -- Alto Neuroscience ( ANRO ) said Wednesday it has started a phase 2 study of ALTO-203 in major depressive disorder patients. Alto said it expects to enroll about 60 adult participants with MDD and anhedonia, with top-line data expected in H1 of 2025. The company said ALTO-203 showed a favorable tolerability profile across...
S&P Global to Offer AI Benchmarking Service
S&P Global to Offer AI Benchmarking Service
Apr 3, 2024
10:53 AM EDT, 04/03/2024 (MT Newswires) -- S&P Global ( SPGI ) said Wednesday it has launched S&P AI Benchmarks by Kensho, a service that evaluates and ranks the quantitative reasoning abilities and expertise of large language models in the business and finance sector. S&P said the service will offer accurate and reliable assessments of LLM applications for financial professionals....
Copyright 2023-2026 - www.financetom.com All Rights Reserved